← Back to Screener
Klotho Neurosciences, Inc. Common Stock (KLTO)
Price$0.34
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-36.94%
Price vs S&P 500 (4W)-36.07%
VGM Score48.43
Market Capitalization$38.55M
All Metrics
Book Value / Share (Quarterly)$0.14
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.08
Price vs S&P 500 (YTD)4.89%
EPS (TTM)$-0.33
10-Day Avg Trading Volume4.61M
EPS Excl Extra (TTM)$-0.33
EPS (Annual)$-0.32
ROI (Annual)-422.10%
Cash / Share (Quarterly)$0.10
ROA (Last FY)-250.28%
EBITD / Share (TTM)$-0.20
Cash Flow / Share (Annual)$-0.11
P/B Ratio3.88x
P/B Ratio (Quarterly)3.43x
Net Income / Employee (Annual)$-2,050,100
Net Interest Coverage (TTM)-16.25x
ROA (TTM)-171.30%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)0.13x
Quick Ratio (Quarterly)82.76x
3-Month Avg Trading Volume4.00M
52-Week Price Return85.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.11
52-Week High$3.91
EPS Excl Extra (Annual)$-0.32
26-Week Price Return-25.56%
Quick Ratio (Annual)0.05x
13-Week Price Return-18.81%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)83.69x
Enterprise Value$31.20M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev136.12%
Net Income / Employee (TTM)$-3,763,400
ROE (Last FY)-518.87%
Net Interest Coverage (Annual)-1.98x
EPS Basic Excl Extra (Annual)$-0.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.33
ROI (TTM)-184.60%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)58.14%
Year-to-Date Return15.92%
5-Day Price Return-5.90%
EPS Normalized (Annual)$-0.32
Month-to-Date Return-5.90%
EBITD / Share (Annual)$-0.30
LT Debt / Equity (Annual)0.14x
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-0.33
P/TBV (Quarterly)4.47x
P/B Ratio (Annual)8.04x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-29.31%
Beta2.40x
Revenue / Share (TTM)$0.00
ROE (TTM)-201.59%
52-Week Low$0.16
mGradeC
vgmGradeC
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KLTOKlotho Neurosciences, Inc. Common Stock | — | — | C | $0.34 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Klotho Neurosciences develops therapies for cancer, cardiovascular, and neurodegenerative diseases using two platforms: a biosimilar biologics program for oncology and a proprietary gene therapy platform that delivers the Klotho protein to treat neurodegeneration. The company's pipeline includes three development-stage candidates: KLTO 101, KLTO 202, and KLTO 301.